WAM
JAZZ icon

Wealthspire Advisors (Maryland)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-73
Closed -$10K – 1229
2019
Q1 		$10K Sell
73
-172
-70% -$22.4K ﹤0.01% 1535
2018
Q4 		$30K Buy
245
+13
+6% +$1.93K ﹤0.01% 1056
2018
Q3 		$39K Buy
232
+10
+5% +$1.72K ﹤0.01% 1054
2018
Q2 		$38K Buy
222
+69
+45% +$11.3K ﹤0.01% 1081
2018
Q1 		$23K Buy
153
+3
+2% +$440 ﹤0.01% 1252
2017
Q4 		$20K Hold
150
– – ﹤0.01% 1329
2017
Q3 		$22K Sell
150
-2
-1% -$302 ﹤0.01% 1273
2017
Q2 		$24K Hold
152
– – ﹤0.01% 1196
2017
Q1 		$22K Buy
152
+150
+7,500% +$19.5K ﹤0.01% 1049
2016
Q4 		$0 Hold
2
– – ﹤0.01% 1799
2016
Q3 		$0 Hold
2
– – ﹤0.01% 1774
2016
Q2 		$0 Hold
2
– – ﹤0.01% 1751
2016
Q1 		$0 Hold
2
– – ﹤0.01% 1798
2015
Q4 		$0 Buy
+2
New +$277 ﹤0.01% 1746

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s JAZZ Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 73 shares — an estimated $10K sold.

Wealthspire Advisors (Maryland) first reported a position in JAZZ in Q4 2015 and held it in 14 quarters. The position peaked at $39K in Q3 2018. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 73 Jazz Pharmaceuticals shares in Q2 2019, an estimated $10K.
  • Wealthspire Advisors (Maryland) first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 14 quarters.
  • Wealthspire Advisors (Maryland)'s Jazz Pharmaceuticals position peaked at $39K in Q3 2018.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.